Welcome to our dedicated page for SkinHealth Systems SEC filings (Ticker: SKIN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SkinHealth Systems Inc. filings document the regulatory record for a Nasdaq-listed medical aesthetics company formerly known as The Beauty Health Company. The filings identify its Class A common stock, operating and financial results, non-GAAP reconciliations, and material-event disclosures tied to quarterly and annual reporting.
Its SEC record also includes proxy materials for annual stockholder voting, board and committee governance, director appointments, officer departures, compensatory arrangements, capital-structure disclosures and shareholder voting matters. These filings provide the formal disclosure framework for the company behind Hydrafacial, SkinStylus and related professional skin-health offerings.
SkinHealth Systems Inc. reported that Sheri Lewis has decided to resign from her role as Chief Operations, Quality and Technology Officer to pursue other business opportunities outside the company. She notified the company on August 10, 2026, and will step down effective August 28, 2026.
The company states that Ms. Lewis’ resignation is not due to any disagreement with SkinHealth Systems, its board of directors, or management regarding operations, policies, or practices.
SkinHealth Systems Inc. Chief Financial Officer Michael P. Monahan reported a Form 4 transaction involving 32,357 shares of Class A Common Stock on 2026-08-10. The shares were withheld by the issuer to satisfy tax withholding requirements upon vesting of restricted stock units, and the disclosure states this does not represent a sale. Following this tax-withholding disposition, Monahan directly holds 1,955,280 shares of Class A Common Stock.
SkinHealth Systems Inc. is asking stockholders at a virtual special meeting on September 22, 2026 to approve a reverse stock split of its Class A common stock at a ratio between 1‑for‑5 and 1‑for‑20, to be chosen later by the board, and to approve potential adjournment of the meeting to solicit more votes if needed.
The main stated goal is to raise the share price to meet Nasdaq’s $1.00 minimum bid requirement after a May 2026 deficiency notice; the stock closed at $0.6610 on August 7, 2026 with 130,140,763 shares outstanding. The company warns that delisting could trigger “Fundamental Change” repurchase rights on its $103.2M 2026 convertible notes and $250.0M 2028 convertible notes, compared with $206.1M of cash, cash equivalents and restricted cash as of June 30, 2026, which could strain liquidity. The reverse split would reduce outstanding shares but leave authorized shares (including 300,000,000 Class A authorized) unchanged, increasing the number of shares available for future issuance and potential dilution.
SkinHealth Systems Inc. reported second quarter 2026 results with net sales of $72.1 million, a decrease of 7.8% from Q2 2025, as both delivery systems and consumables sales declined. The company sold 770 delivery systems, down from 957, while its active installed base grew to 36,516 systems.
Profitability metrics improved. Gross margin rose to 68.4% (adjusted 71.8%) from 62.8%, and operating expenses fell to $45.8 million from $51.8 million, reflecting lower personnel-related costs. SkinHealth posted a net loss of $2.7 million versus prior-year net income of $19.7 million, largely because Q2 2025 included an $18.1 million gain related to exchanges and repurchases of its 2026 notes. Adjusted EBITDA increased to $17.0 million, up from $13.9 million, with margin improving to 23.6%.
For the third quarter of 2026, management projects net sales of $65–$70 million and adjusted EBITDA of $5–$7 million. Full-year 2026 guidance calls for net sales of $280–$290 million and adjusted EBITDA of $39–$46 million. Cash, cash equivalents, and restricted cash totaled $206.1 million at June 30, 2026.
SkinHealth Systems Inc. is calling a virtual special stockholder meeting on September 22, 2026 to vote on a reverse stock split and a possible adjournment of the meeting. The reverse split would combine outstanding Class A common shares at a Board-selected ratio between 1-for-5 and 1-for-20, with authority for the Board to implement, delay or abandon it within one year.
The main stated objective is to raise the share price to meet Nasdaq Capital Market’s $1.00 minimum bid requirement after the stock closed at $0.6986 on July 28, 2026 and the company received a Nasdaq deficiency notice, with an initial compliance deadline of November 4, 2026. The filing explains that a Nasdaq delisting could trigger a “Fundamental Change” under its 1.25% 2026 and 7.95% 2028 convertible notes, potentially giving holders the right to demand cash repurchase of up to $353.2 million of principal, compared with $204.4 million of cash, cash equivalents and restricted cash reported as of March 31, 2026.
The reverse split would not change authorized share counts but would increase the number of authorized and unissued shares relative to shares outstanding, with potential dilution in future issuances. Fractional shares would be settled in cash. The Board unanimously recommends voting “FOR” both the reverse split and the adjournment proposal.
BlackRock, Inc. filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership of Class A Stock of SKINHEALTH SYSTEMS INC. BlackRock reports beneficial ownership of 1,301,291 shares, representing 1.0% of the outstanding Class A Stock.
BlackRock has sole voting power and sole dispositive power over all 1,301,291 shares, with no shared voting or dispositive power. Various persons have rights to receive dividends or proceeds from these shares, but no individual person has an interest in more than five percent of the total outstanding common shares.
BlackRock Portfolio Management LLC reported beneficial ownership of Class A stock of SKINHEALTH SYSTEMS INC. BlackRock holds 7,214,912 shares, representing 5.6% of the outstanding Class A shares.
BlackRock reports sole voting power and sole dispositive power over all 7,214,912 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of SKINHEALTH SYSTEMS INC.’s outstanding common shares.
Capricorn Fund Managers Limited filed an amended Schedule 13G reporting a passive ownership position in SkinHealth Systems Inc. Class A ordinary shares. Capricorn reports beneficial ownership of 22,276,935 shares, representing 17.2% of this class.
Capricorn holds sole voting and sole dispositive power over all 22,276,935 shares, with no shared voting or dispositive power reported. The filing is signed by Parth R. Karia, Head of Risk, who also certifies that Capricorn, as a foreign investment adviser regulated by the FCA, is subject to a regulatory scheme comparable to that of a functionally equivalent U.S. institution.
SKINHEALTH SYSTEMS INC ownership update: FMR LLC reports beneficial ownership of 10,201,685 shares of Class A Common Stock, representing 7.9% of the class as shown on the cover date 06/30/2026. The filing is Amendment No. 9 to a Schedule 13G/A and identifies sole voting and sole dispositive power over the listed shares.